Collegium Pharmaceutical, Inc. (COLL) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings per Share (Diluted) | 1.76 USD_per_share | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 103.9M | FY2026-Q1 |
| Adjusted Operating Expenses Excluding Stock-Based Compensation | 69.3M | FY2026-Q1 |
| Product Revenue, Net | 193.5M | FY2026-Q1 |
| Belbuca Net Revenue | 52.6M | FY2026-Q1 |
| Xtampza Extended Release Net Product Revenue | 50.8M | FY2026-Q1 |
| Jornay Net Revenue | 38.9M | FY2026-Q1 |
| Journee Total Prescribers | 30K | FY2026-Q1 |
| Pain Portfolio Net Revenue | 154.6M | FY2026-Q1 |
| Nucenta Franchise Net Revenue | 47M | FY2026-Q1 |
| Jornay PM Prescriptions Written | 206K | FY2026-Q1 |
| Adjusted Net Income | 80.3M | FY2025-Q4 |
| Jornay PM Prescriptions Growth Quarter Over Quarter | 20.00 percent | FY2025-Q3 |
| Belbuca Total Prescriptions Growth Quarter Over Quarter | 2.90 percent | FY2024-Q4 |
Back to COLL overview · COLL earnings · COLL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.